Last reviewed · How we verify
Cravit
Cravit is a Small molecule drug developed by Chang Gung Memorial Hospital. It is currently in Phase 1 development. Also known as: Levofloxacin.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cravit |
|---|---|
| Also known as | Levofloxacin |
| Sponsor | Chang Gung Memorial Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Hyaluronic Acid-containing Artificial Tears in Post-cataract Surgery Dry Eye Disease (PHASE4)
- Safety Profile Comparison of Undiluted Intracameral Moxifloxacin vs. Levofloxacin in Cataract Surgery (PHASE1)
- Efficacy of Combination Therapy With Minocycline for Treatment of Stenotrophomonas Maltophilia Infections (PHASE4)
- Intraluminal Mono-antibiotic Therapy for Helicobacter Pylori Infection - A Comparison of Levofloxacin Powder and Levofloxacin Solution (PHASE4)
- The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% (PHASE1, PHASE2)
- The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% (PHASE1, PHASE2)
- Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cravit CI brief — competitive landscape report
- Cravit updates RSS · CI watch RSS
- Chang Gung Memorial Hospital portfolio CI
Frequently asked questions about Cravit
What is Cravit?
Who makes Cravit?
Is Cravit also known as anything else?
What development phase is Cravit in?
Related
- Manufacturer: Chang Gung Memorial Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Levofloxacin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing